Bionomics Lead Drug Is A Potential Game-changer
Bionomics (BNOX) is a clinical-stage company with novel drug candidates for the treatment of the central nervous system ("CNS"). The company's leading candidate, BNC210, has completed phase II for FDA clearance for the treatment of social anxiety disorder ("SAD") and post-traumatic stress disorder ("PTSD"). The Bionomics pipeline also includes MK-4334, …
Keep reading with a 7-day free trial
Subscribe to Microcap Opportunities to keep reading this post and get 7 days of free access to the full post archives.